These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7971733)

  • 1. Effects of D1 and D2 agonists on spontaneous motor activity in MPTP treated mice.
    Fredriksson A; Plaznik A; Sundström E; Archer T
    Pharmacol Toxicol; 1994 Jul; 75(1):36-41. PubMed ID: 7971733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
    Gnanalingham KK; Erol DD; Hunter AJ; Smith LA; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1995 Feb; 117(3):275-86. PubMed ID: 7770603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
    Rouillard C; Bédard PJ; Di Paolo T
    Eur J Pharmacol; 1990 Aug; 185(2-3):209-15. PubMed ID: 2253695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.
    Archer T; Palomo T; McArthur R; Fredriksson A
    Neurotox Res; 2003; 5(1-2):95-110. PubMed ID: 12832225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine receptors and sensorimotor behavior in MPTP-treated mice.
    Weihmuller FB; Hadjiconstantinou M; Bruno JP
    Behav Brain Res; 1990 May; 38(3):263-73. PubMed ID: 1973042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists.
    Gagnon C; Bédard PJ; Di Paolo T
    Eur J Pharmacol; 1990 Mar; 178(1):115-20. PubMed ID: 1970537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
    Morissette M; Grondin R; Goulet M; Bédard PJ; Di Paolo T
    J Neurochem; 1999 Feb; 72(2):682-92. PubMed ID: 9930741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine receptor agonist reduces ethanol self-administration in the ethanol-preferring C57BL/6J inbred mouse.
    Ng GY; George SR
    Eur J Pharmacol; 1994 Nov; 269(3):365-74. PubMed ID: 7895775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of dopamine agonists on locomotion in intact and reserpine-treated mice.
    Zarrindast MR; Eliassi A
    Gen Pharmacol; 1991; 22(6):1027-31. PubMed ID: 1687393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of D1 and D2 dopamine receptors increases the activity of the somatostatin receptor-effector system in the rat frontoparietal cortex.
    Izquierdo-Claros RM; del Boyano-Adánez M; Arilla-Ferreiro E
    J Neurosci Res; 2000 Oct; 62(1):91-8. PubMed ID: 11002291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
    Gagnon C; Gomez-Mancilla B; Markstein R; Bédard PJ; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):667-76. PubMed ID: 8588064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
    Nomoto M; Jenner P; Marsden CD
    Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioural role of dopamine D1 receptors in the reserpine-treated mouse.
    Starr BS; Starr MS; Kilpatrick IC
    Neuroscience; 1987 Jul; 22(1):179-88. PubMed ID: 2957609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D1/D2 agonists injected into nucleus accumbens and ventral pallidum differentially affect locomotor activity depending on site.
    Gong W; Neill DB; Lynn M; Justice JB
    Neuroscience; 1999; 93(4):1349-58. PubMed ID: 10501459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
    Engber TM; Marin C; Susel Z; Chase TN
    Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats.
    Robertson GS; Robertson HA
    Brain Res; 1986 Oct; 384(2):387-90. PubMed ID: 2946360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.
    Blanchet PJ; Grondin R; Bédard PJ; Shiosaki K; Britton DR
    Eur J Pharmacol; 1996 Aug; 309(1):13-20. PubMed ID: 8864687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.
    Nomoto M; Jenner P; Marsden CD
    Neurosci Lett; 1988 Nov; 93(2-3):275-80. PubMed ID: 2907373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D
    Mailman RB; Yang Y; Huang X
    Eur J Pharmacol; 2021 Feb; 892():173760. PubMed ID: 33279520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.